Clinical trials: Under Nutrition
Obesity
Comparison of MAG and Fish Oil Efficacy
A potential application for unstructured monoacylglycerol (MAG) containing long chain polyunsaturated fatty acids (LC-PUFA)can be to provide essential fatty acids to humans who chronically consume lipases inhibitor such as…
- Trial name
- NCT01797757
- Testing
- Fish oil enriched with EPA, MAG-EPA oil, Orlistat
- Where
- Switzerland
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Micronutrient Deficiencies
The Effect of Micronutrient Supplementation on Nutrition Status and Well-being
Inadequate micronutrient status poses a significant challenge in Sub-Saharan African countries, including Ghana, and affects various demographics.
- Trial name
- NEXUS (NCT07031973)
- Testing
- Active Effervescent Powder, Nutrition training and healthy lifestyle coaching
- Where
- Ghana
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- InnoNext Sarl
Diabetes Mellitus, Type 2
Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition
Primary Objective: 1- Proportion of patients with mean daily glycemia <140mg/dL during the period of 7 days of treatment with glargine plus supplemental glulisine versus patients with glulisine sliding scale.
- Trial name
- NCT01081938
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE
- Where
- 10 sites in Brazil
- Volunteers
- 15 people
- Sponsor
- Sanofi
Obesity
A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects
Approximately 60 obese, but otherwise healthy, subjects will be assessed in this benchmark study to investigate the physiological changes associated with weight loss and regain.
- Trial name
- NCT01597609
- Testing
- sibutramine
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity, Insulin Resistance
The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects
The primary objective of this study is to determine whether MICARDIS® improves insulin sensitivity in overweight or obese, non-diabetic, normotensive subjects.
- Trial name
- NCT00146289
- Testing
- MICARDIS® (telmisartan)
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 138 people
- Sponsor
- Boehringer Ingelheim
Obesity
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight.
- Trial name
- NCT04775082
- Testing
- Liraglutide
- Where
- 32 sites in United States, Belgium and 7 more
- Volunteers
- 78 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin
The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as injections under the skin
- Trial name
- NCT06064006
- Testing
- NNC0487-0111
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
The purpose of this study is to evaluate the effects of a new daily subcutaneous (SC) injectable formulation of setmelanotide (RM-493) in healthy participants with obesity on mean percent body weight loss and other weight loss…
- Trial name
- NCT02041195
- Testing
- Setmelanotide
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Feeding Behavior, Nutrients Intakes
Nutri-Bébé 2022 A French National Survey on Feeding Practice and Nutrient Intakes of Children Under 3 Years of Age
The Nutri-Bébé 2022 survey is an observational cross-sectional study aiming to update food consumption, practices and nutrient intakes in children under 3 years of age in metropolitan France.
- Trial name
- NBB2022 (NCT05649527)
- Where
- France
- Volunteers
- 1,224 people
- Sponsor
- Secteur Français des Aliments de l'Enfance
Mesopic Vision, Night Vision Loss
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
Safety and efficacy of 0.75% Phentolamine Ophthalmic Solution to improve mesopic low contrast visual acuity in subjects with post-refractive surgery visual disturbances.
- Trial name
- LYNX-2 (NCT06349759)
- Testing
- phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Opus Genetics, Inc
Cancer-related Malnutrition
Efficacy Study of Long-term Parenteral Nutrition With SmofKabiven® E in Lung Cancer Patients Under Anticancer Therapy
The purpose of this study is to determine the efficacy of long-term addition of SmofKabiven® E to normal oral nutrition after routine dietary counseling as compared to standard of care nutrition in which oral nutrition is the…
- Trial name
- NCT03355079
- Testing
- SmofKabiven® E
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Fresenius Kabi
Obese
Pharmacodynamics and Pharmacokinetics of Different Glucose Bead Formulations in Obese Healthy Subjects
The goal of this clinical study was to assess pharmacodynamics (PD) and pharmacokinetics (PK) of different Glucose beads formulations in obese healthy subjects under fasting condition. The study was designed in 2 parts.
- Trial name
- NCT05737927
- Testing
- Glucose 8 g coated beads (47% w/w), Glucose 12 g coated beads (47% w/w), Glucose 16 g coated beads (47% w/w)
- Where
- Romania
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Aphaia Pharma US LLC
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Children, Under-nutrition
Compliance With Dietary Recommendations in Children at Risk for Undernutrition
This study will assess compliance with dietary recommendations, in conjunction with a nutritional supplement to meet the nutritional requirements in children and the effects of the compliance on promoting growth in children who…
- Trial name
- NCT01658267
- Testing
- nutritional supplement
- Where
- 2 sites in Philippines
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Secondary Hyperparathyroidism, Chronic Kidney Disease
Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis
Paricalcitol capsules (Zemplar®) received marketing authorization in Sweden in late 2007 for the prevention and treatment of secondary hyperparathyroidism in patients with Stage 3 \& 4 Chronic Kidney Disease (CKD).
- Trial name
- CAPITOL (NCT01265992)
- Where
- 10 sites in Sweden
- Volunteers
- 50 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Obesity & Overweight, Weight Loss
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health…
- Conditions
- Obesity & Overweight, Weight Loss, Preventative Health, Body Weight
- Trial name
- FLOURISH (NCT07588984)
- Testing
- Noom Weight, Free Tier, Education-only control
- Where
- United States
- Volunteers
- 2,310 people
- Sponsor
- Noom Inc.
Overweight, Obesity
A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.
The study is testing a new medicine (NNC0487-0111) for weight control in Chinese people with BMI between 24 kilogram per meter square (kg/m2) and 34.9 kg/m2.
- Trial name
- NCT07121153
- Testing
- NNC0487-0111 A
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.
- Trial name
- NCT06313528
- Testing
- LY3437943
- Where
- 3 sites in United States
- Volunteers
- 85 people
- Sponsor
- Eli Lilly and Company
Obesity
Special Use - Results Surveillance on Long-term Use With Wegovy®
The purpose of the study is to investigate the safety and effectiveness of Wegovy® in patients with obesity disease under real-world clinical practice in Japan. Participants will get Wegovy® as prescribed by the study doctor.
- Trial name
- NCT06283667
- Testing
- Semaglutide
- Where
- 112 sites in Japan
- Volunteers
- 1,071 people
- Sponsor
- Novo Nordisk A/S
Obesity, Genetic Obesity
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor…
- Trial name
- NCT05093634
- Testing
- Setmelanotide
- Where
- 56 sites in United States, Canada and 8 more
- Volunteers
- 296 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.